- As Actavis finalizes its $66 billion acquisition of Allergan, the company is also taking the Allergan name as part of its increased focus on patent-protected, brand-name drugs.
- Actavis is the world's third-largest generics drug company, but is trying to focus more on brand-name drugs, which are more profitable. Actavis has also increased its development and marketing of branded medications, independent of its acquisition of Allergan.
- Based on Q4 2014 results, 45% of Actavis' revenues were from brand-name drugs.
Actavis, which will soon be known as Allergan, is becoming a powerhouse of a company through dint of planning, R&D, and well-planned acquisitions—including both the dramatic acquisition of Allergan in November and the acquisition of Auden McKenzie last month.
With Allergan acquisition, which includes the company's flagship Botox, Acatvis is solidifying its status as a major player in both generics and brand-name medications. Even without this acquisition, things have been going pretty well for Actavis, which had better-than-expected revenues and earnings in 2014.
In Q4, revenues increased 44% to $4.01 billion, while FY 2014 revenues increased 47% to $12.7 billion. The Allergan deal is slated to close within the next two to three months.